Vivos Therapeutics, Inc.

VVOS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Market Cap$33,987$28,716$24,497$25,266
- Cash$3,087$4,402$2,342$6,260
+ Debt$4,119$11,581$1,399$1,512
Enterprise Value$35,019$35,895$23,554$20,518
Revenue$6,783$3,820$3,016$3,698
% Growth77.6%26.7%-18.4%
Gross Profit$3,937$2,110$1,509$2,097
% Margin58%55.2%50%56.7%
EBITDA-$5,016-$4,707-$3,564-$2,683
% Margin-73.9%-123.2%-118.2%-72.6%
Net Income-$5,400-$5,013-$3,864-$2,827
% Margin-79.6%-131.2%-128.1%-76.4%
EPS Diluted-0.49-0.55-0.45-0.48
% Growth10.9%-22.2%6.2%
Operating Cash Flow-$4,161-$3,494-$3,796-$2,940
Capital Expenditures$893-$771-$122-$165
Free Cash Flow-$3,268-$4,265-$3,796-$3,105
Vivos Therapeutics, Inc. (VVOS) Financial Statements & Key Stats | AlphaPilot